Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy
Ho, G. Y.; Kyran, E.; Bedo, J.; Wakefield, M.; Ennis, D.; Mirza, H.; Cooke, S.; Lieschke, E.; Vandenberg, C.; Kondrashova, O.; Upstill-Goddard, R.; Bailey, U.-M.; Biankin, S.; Roxburgh, P.; Glasspool, R.; Bryson, G.; Biankin, A.; Ratnayake, G.; McNally, O.; Traficante, N.; DeFazio, A.; Bowtell, D.; McNeish, I.; Papenfuss, A.; Scott, C.; Barker, H.
Show abstract
Ovarian carcinosarcoma (OCS) is an aggressive and rare tumour type with limited treatment options. OCS is hypothesised to develop via the combination theory from a single progenitor, resulting in carcinomatous and sarcomatous components, or alternatively via the conversion theory, with the sarcomatous component developing from the carcinomatous component through epithelial-to-mesenchymal transition (EMT). We show OCS from 18 women to be monoclonal through analysis of DNA variants from isolated carcinoma and sarcoma components. RNA sequencing indicated the carcinoma components were more mesenchymal when compared with pure ovarian carcinomas, supporting the conversion theory. We used pre-clinical OCS models to test the efficacy of microtubule-targeting drugs, including eribulin, which has been shown to reverse EMT characteristics. We demonstrated that microtubule inhibitors, vinorelbine and eribulin, were more effective than standard-of-care platinum-based chemotherapy. Eribulin reduced mesenchymal characteristics, N-MYC expression and cholesterol biosynthesis. Finally, eribulin induced a strong immune response, supporting immunotherapy combinations in the clinic.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma 94%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 94%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 94%
Similar papers in this journal
- Artificial intelligence-based histopathology image analysis identifies a novel subset of endometrial cancers with distinct genomic features and unfavourable outcome 95%
- Chronic circadian disruption modulates breast cancer cell stemness and their immune microenvironment to drive metastasis in mice 95%
- Spatial transcriptomics reveals ovarian cancer subclones with distinct tumour microenvironments 95%
Similar papers in this journal
- Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer 95%
- Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification 94%
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236 94%
Similar papers in this journal
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 96%
- Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma 95%
- Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.